

# Harmine stimulates proliferation of human neural progenitors

Vanja Dakic<sup>1,2</sup>, Renata de Moraes Maciel<sup>1</sup>, Hannah Drummond<sup>1,2</sup>, Juliana M Nascimento<sup>1,3</sup>, Pablo Trindade<sup>1</sup>, Stevens K Rehen<sup>Corresp. 1,2</sup>

<sup>1</sup> IDOR, D'Or Institute for Research and Education, Rio de Janeiro, RJ, Brazil

<sup>2</sup> Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil

<sup>3</sup> Department of Biochemistry and Tissue Biology / Institute of Biology, State University of Campinas (UNICAMP), Campinas, SP, Brazil

Corresponding Author: Stevens K Rehen

Email address: srehen@lance-ufrrj.org

Harmine is the  $\beta$ -carboline alkaloid with the highest concentration in the psychotropic plant decoction Ayahuasca. In rodents, classical antidepressants reverse the symptoms of depression by stimulating neuronal proliferation. It has been shown that Ayahuasca presents antidepressant effects in patients with depressive disorder. In the present study, we investigated the effects of harmine in cell cultures containing human neural progenitor cells (hNPCs, 97% nestin-positive) derived from pluripotent stem cells. After 4 days of treatment, the pool of proliferating hNPCs increased by 71.5%. Harmine has been reported as a potent inhibitor of the dual specificity tyrosine-phosphorylation-regulated kinase (DYRK1A), which regulates cell proliferation and brain development. We tested the effect of analogs of harmine, an inhibitor of DYRK1A (INDY), and an irreversible selective inhibitor of monoamine oxidase (MAO) but not DYRK1A (pargyline). INDY but not pargyline induced proliferation of hNPCs similarly to harmine, suggesting that inhibition of DYRK1A is a possible mechanism to explain harmine effects upon the proliferation of hNPCs. Our findings show that harmine enhances proliferation of hNPCs and suggest that inhibition of DYRK1A may explain its effects upon proliferation *in vitro* and antidepressant effects *in vivo*.

**Title: Harmine stimulates proliferation of human neural progenitors**

Authors: Vanja Dakic<sup>1,2</sup>, Renata de Moraes Maciel<sup>1</sup>, Hannah Drummond<sup>1,2</sup>,  
Juliana M. Nascimento<sup>1,3</sup>, Pablo Trindade<sup>1</sup>, Stevens K. Rehen<sup>1,2,\*</sup>

<sup>1</sup>D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil

<sup>2</sup>Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil

<sup>3</sup>Department of Biochemistry and Tissue Biology, Institute of Biology, State University of Campinas, Campinas, SP, Brazil

\*Corresponding author: S.K.R. (srehen@lance-ufrj.org)

**Abstract**

Harmine is the  $\beta$ -carboline alkaloid with the highest concentration in the psychotropic plant decoction Ayahuasca. In rodents, classical antidepressants reverse the symptoms of depression by stimulating neuronal proliferation. It has been shown that Ayahuasca presents antidepressant effects in patients with depressive disorder. In the present study, we investigated the effects of harmine in cell cultures containing human neural progenitor cells (hNPCs, 97% nestin-positive) derived from pluripotent stem cells. After 4 days of treatment, the pool of proliferating hNPCs increased by 71.5%. Harmine has been reported as a potent inhibitor of the dual specificity tyrosine-phosphorylation-regulated kinase (DYRK1A), which regulates cell proliferation and brain development. We tested the effect of analogs of harmine, an inhibitor of DYRK1A (INDY), and an irreversible selective inhibitor of monoamine oxidase (MAO) but not DYRK1A (pargyline). INDY but not pargyline induced proliferation of hNPCs similarly to harmine, suggesting that inhibition of DYRK1A is a possible mechanism to explain harmine effects upon the proliferation of hNPCs. Our findings show that harmine enhances proliferation of hNPCs and suggest that inhibition of DYRK1A may explain its effects upon proliferation *in vitro* and antidepressant effects *in vivo*.

**Introduction**

Throughout life, specific regions in the human adult brain continuously generate neural cells from a pool of neural progenitor cells (hNPCs). Many physiological and pathological events are able to control neurogenesis by modulating proliferation, differentiation, maturation and integration of new-born neurons into the existing circuitry (Zhao et al. 2008). This balance can be disrupted by chronic stress (Egeland et al. 2015), depression (Mahar et al. 2014), aging (DeCarolis et al. 2015), and neurodegenerative diseases (Winner & Winkler 2015).

Classical antidepressants can reverse or block stress-induced hippocampal atrophy in rodents, mostly by stimulating neuronal proliferation (Malberg et al. 2000)). Fluoxetine, one of the most used selective serotonin reuptake inhibitors, induces proliferation of rat hypothalamic (Chen et al. 2007; Sachs & Caron 2015; Sousa-Ferreira et al. 2014)) and hippocampal neural progenitors *in vitro* and *in vivo* (Chen et al. 2007; Sachs & Caron 2015). Unfortunately, treatment with classic antidepressants leads to full remission in only 50% of patients (Nestler et al. 2002), causes side effects and the time required for achieving therapeutic response is usually measured in weeks. Thus, the demand for novel psychopharmacological agents able to revert depression remains significant.

Beta-carbolines, a large group of indole alkaloids are widely distributed in plants. Two members of this group, harmine and harmaline, have been found in human plasma after ingestion of Ayahuasca (Callaway et al. 1996), a psychotropic beverage traditionally used in the Amazonian region of South America as part of local religious ceremonies (Labate & Feeney 2012).

Evaluation of the effects of a single dose of Ayahuasca in six volunteers with a current depressive episode suggested that this plant decoction has fast-acting anxiolytic and antidepressant effects (Osorio Fde et al. 2015). Moreover, the use of harmine in rodents leads to the reduction of symptoms associated with depression (Farzin & Mansouri 2006) and re-establishment of normal levels of hippocampal brain-derived neurotrophic factor (BDNF) (Fortunato et al. 2009).

Apart of these initial studies, there are no data available regarding the neurogenic effects of harmine in humans. Here we examine the effects of harmine on the proliferation of human neural progenitor cells derived from

pluripotent stem cells. We show that harmine increased the pool of neural progenitor cells and that inhibition of DYRK1 is the possible mechanism involved in those proliferative effects.

## **Material and methods**

### **Chemicals**

Harmine (286044), INDY (SML1011), and pargyline hydrochloride (P8013) were purchased from Sigma-Aldrich and diluted in DMSO. Subsequent dilutions were made in aqueous solution. Click-it EdU kit and BOBO™-3 were purchased from Thermo Fisher Scientific. All controls received an amount of vehicle equivalent to drug treatment conditions and no significant difference was observed between controls with (DMSO) or without vehicle.

### **Human pluripotent stem cells**

Human embryonic stem cells (Fraga et al. 2011) were cultured under feeder-free culture conditions on Matrigel (BD Biosciences)-coated dishes (Corning) in Essential 8™ Medium (Thermo Fisher Scientific). Passaging was performed enzymatically using Accutase (Millipore) by splitting colonies in clumps every 4-5 days and re-plating on Matrigel-coated dishes, having their medium changed every day. All cells were maintained at 37°C in humidified air with 5% CO<sub>2</sub>.

### **Human neural progenitor cells**

To induce embryonic stem cells to direct neural differentiation, we performed an adaptation of Baharvand and co-workers protocol (Baharvand et al. 2007; Paulsen Bda et al. 2012). Briefly, 70% confluent BR1 culture was differentiated to the neural lineage in defined adherent culture by retinoic acid and basic fibroblast growth factor (bFGF) within 18 days of culture. On the 18th day neural tube-like structures were collected and replated on dishes coated with 10 µg/mL of Poly-L-ornithine and 2.5 µg/mL of laminin (Thermo Fisher Scientific). A population of hNPCs that migrated from neural tube-like structures was tested for expression of neuronal markers and expanded. Expansion was done in N2B27 medium

supplemented with 25 ng/mL bFGF and 20 ng/mL EGF (Thermo Fisher Scientific). N2B27 medium consisted of DMEM/F-12 supplemented with 1X N2, 1X B-27, 1% penicillin/streptomycin (Thermo Fisher Scientific). Cells were incubated at 37 °C and 5% CO<sub>2</sub>. Medium was replaced every other day. hNPCs were expanded for no more than 5 passages.

## High Content Screening

Cell proliferation, cell death and DNA damage experiments were performed in a High Content Screening (HCS) format. hNPCs (1,500 cells/per well) were plated on a multiwell 384 µClear plate (Greiner Bio-One) coated with 100 µg/mL Poly-L-ornithine and 10 µg/mL laminin (Thermo Fisher Scientific). After 24h, cells were treated for 4 days in quintuplicate (five wells per condition) with harmine, INDY and pargyline in N2B27 medium supplemented with bFGF and EGF. On day 4 cells were labelled with 10 µM EdU for 2h (cell proliferation) or BOBO™-3 (cell death) for 30 min prior to fixation or image acquisition, respectively.

## High Content Analysis

All images were acquired on Operetta high-content imaging system (Perkin Elmer). For proliferation, incorporated EdU was detected with Alexa Fluor 488 using Click-iT EdU kit following manufacturer's instruction. Immunocytochemistry for Ki-67 was performed after EdU AF488 labelling. Total number of cells was calculated by nuclei stained with DAPI. S phase was determined by percentage of total cells labelled with EdU. Whereas dividing cells in all phases of cell cycle, exempting G<sub>0</sub>, were measured by Ki-67 positive cells as percentage of total cells. Images were acquired with a 10x objective with high numerical aperture (NA).

For cell death analysis, cells were labelled with a fluorophore dye cocktail, containing the cell-permeant nuclear dye Hoechst and the cell-impermeant nuclear dye BOBO™-3 in fresh N2B27 medium for 30 min at 37 °C and 5% CO<sub>2</sub>. After incubation, the dye cocktail was replaced for new medium and live cell imaging was performed using temperature and CO<sub>2</sub> control option (TCO) of

Operetta, set to 37°C and 5% CO<sub>2</sub> at 10x magnification. For DNA damage analysis, immunocytochemistry was performed on fixed cells after 4 days of treatment using H2AX antibody, and images were acquired at 10x magnification. All quantification analysis were normalised to the number of cells in the well segmented by nucleus dyes. H<sub>2</sub>O<sub>2</sub> was used as positive control for both cell death and DNA damage.

All analyses sequences were designated by combining segmentation steps with morphological and fluorescence based object characterizations using the image analysis software Harmony 3.5.1 (Perkin Elmer).

### **Immunocytochemistry**


hNPCs were fixed in formaldehyde 3.7% for 15 min at RT and permeabilized in 0.2% Triton X-100 for 15 min. Primary antibodies were incubated overnight in 2% BSA at 4°C, following 40 min of 2% BSA blockage. After washing with PBS, secondary antibodies were incubated for 1h at RT in the dark. Cells were washed 3 times with PBS and nuclei were stained with DAPI. Coverslips were mounted on slides using Aqua-Poly Mount (Polysciences) whereas cells on the 384 well plates were covered with glycerol and sealed with AlumaSeal CS (Excel Scientific) for image acquisition in confocal microscopy (Leica) and Operetta (Perkin Elmer), respectively. Primary antibodies used: mouse anti-MAP2 (Sigma-Aldrich), mouse anti-Ki-67 (BD Biosciences), rabbit anti-PAX6 (Santa Cruz Biotechnology), rabbit anti-GFAP (Dako), rabbit anti-γ-H2AX (Cell Signaling Technology), rabbit anti-FOXG1 (Abcam), rabbit anti-DYRK1A (Sigma-Aldrich), rabbit anti-SOX2 (Millipore), mouse anti-β-tubulin III (Millipore), mouse anti-nestin (Millipore), rabbit anti-TBR2 (Millipore). Secondary antibodies used: goat anti-mouse Alexa Fluor 594 and goat anti-rabbit Alexa Fluor 488 (Thermo Fisher Scientific). Data are expressed as relative protein expression in comparison with basal protein expression in control with vehicle (DMSO).

### **Statistical analysis**

All data are expressed as mean  $\pm$  sem. Results were accepted as statistically significant at  $p < 0.05$ , as determined using one-way ANOVA with Tukey's multiple comparison test. A minimum of 10,000 hNPCs was counted per condition/per experiment.

## Results

We generated hNPCs from human embryonic stem cells using a protocol that recapitulates the early steps of nervous system development (Baharvand et al. 2007). Characterization of specific cell markers was done on day 0 (Supplementary Fig. 1). More than 90% of the hNPCs express characteristic markers of neural progenitors, such as SOX2 (sex determining region Y-box 2), nestin (intermediate filament protein; neuroectodermal stem cell marker), PAX6 (paired box 6), FOXG1 (forkhead box G1; transcriptional repressor important for development of the brain and telencephalon), TBR2 (transcription factor Eomes; key regulator of neurogenesis in the subventricular zone) (Fig. 1a, b, d, e, g). Additionally, differentiated cells expressing  $\beta$ -Tubulin III (a class III member of the  $\beta$  tubulin protein family primarily expressed in neurons), GFAP (glial fibrillary acidic protein, marker of astrocytes), or MAP2 (marker of neuronal soma and dendrites) are also observed (Fig. 1b, c, g). Ninety percent of cells express the dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) (Fig. 1f, g).




**Figure 1: Characterization of neural progenitor cells derived from human embryonic stem cells.** Representative images showing hNPCs stained for (a) TBR2 and Nestin, (b) PAX6 and  $\beta$ -Tubulin III, (c) GFAP and MAP2, (d) SOX2, (e) FOXG1, (f) DYRK1A. (g) Quantification of cell markers. (h) Venn diagram showing percentage of double stained cells. A minimum of 10,000 hNPCs was counted per marker. Scale bar: 25  $\mu$ m.

# **Harmine increases proliferation of human neural progenitors: a possible role of DYRK1**

Pharmacokinetic studies have shown a high variability in the bioavailability of ayahuasca alkaloids in the human plasma: 36.4-222.3 ng/mL (Callaway et al. 1996), 0.5-5 ng/mL (Yritia et al. 2002). On the other hand, *in vitro* studies have been using a wide spectrum of harmine concentrations, ranging from 333 nM to 22.5  $\mu$ M (Gockler et al. 2009; Hammerle et al. 2011; Martinez de Lagran et al. 2012; Mazur-Kolecka et al. 2012; Wang et al. 2015). In order to examine its effects upon proliferation, we incubated human neural cells with harmine ranging from 0.1 to 22.5  $\mu$ M for 96h (Supplementary Figs. 1 and 2). The 7.5  $\mu$ M concentration of harmine was the most effective on proliferation of hNPCs (Supplementary Fig. 2), increasing the pool of proliferating cells by 71.5% (Fig.




197 2a, b). No evidence of cell death or DNA damage in response to harmine as  
 198 measured by BOBO-3 (Fig. 3a, b) and H2AX labelling (Fig. 3c, d) was observed.  
 199 Treatment with harmine increased by 64.4% the specific pool of neural  
 200 progenitors, which actively participates in adult neurogenesis (Nestin and GFAP  
 201 labelled, Fig 2c, d) (Fukuda et al. 2003). The number of cells positive for SOX2,  
 202 MAP2 and FOXG1 was not altered (Supplementary Fig. 3).



203

204 **Figure 2: Quantification of the proliferation and differentiation of hNPCs**  
 205 **after treatment with harmine.** (a) Representative images of EdU staining. (b)  
 206 Cell proliferation (S phase) relative to DMSO control, measured by EdU  
 207 incorporation. (c) Representative images of GFAP and Nestin staining. (d)  
 208 Expression of Nestin and GFAP proteins relative to DMSO control. A minimum of  
 209 10,000 hNPCs was counted per condition/per experiment. Data were analysed  
 210 by one-way ANOVA with Tukey's multiple comparison test, \*\*  $p < 0.001$ ,  
 211 \*\*\*  $< 0.0001$ . Values represent mean  $\pm$  sem. The number inside the bar represents  
 212 the number of experiments in each group. Scale bar: 100  $\mu$ m.


213



**Figure 3: Percentage of cell death and DNA damage in neural cells treated with harmine.** (a) Representative immunostaining images of BOBO-3 (red) positive cells. Nuclei are stained with Hoechst (blue). (b) Cell death relative to DMSO control, measured as the percentage of cells stained with BOBO-3. (c) Representative images of cells positive for H2AX (green). Nuclei are stained with DAPI (blue). (d) Quantification of H2AX positive cells relative to DMSO control, as percentage of cells stained with H2AX. H<sub>2</sub>O<sub>2</sub> was used as positive control for both cell death and DNA damage. A minimum of 10,000 hNPCs was counted per condition/per experiment. Data were analysed by one-way ANOVA with Tukey's multiple comparison test, \*  $p < 0.05$ , \*\*\*  $p < 0.0001$ . Values represent mean  $\pm$  sem. The number inside the bar represents the number of experiments in each group. Scale bar: 100  $\mu$ m.

Harmine has been shown to be an inhibitor of DYRK1A (Becker & Sippl 2011; Gockler et al. 2009), other DYRK family members (Gockler et al. 2009) and monoamine oxidase (MAO) (Santillo et al. 2014). To verify whether these two targets are involved in the harmine-dependent increase in neural proliferation, we examined the effect of two functional analogs of harmine in human neural cells: INDY (15  $\mu$ M), an inhibitor of DYRK1A; and pargyline (10  $\mu$ M), an irreversible

selective inhibitor of MAO but not DYRK1A. Harmine and INDY increased proliferation of hNPCs in comparison with control, analysed by two different methods, while pargyline did not induce the same effect. Concomitant inhibition of both DYRK1A and MAOs produced similar effect as harmine or INDY alone (Fig. 4).



**Figure 4: Quantification of EdU and Ki-67 labelling in human neural progenitor cells in response to harmine and its functional analogs.** (a) Cell proliferation relative to DMSO control, measured by EdU incorporation. (b) Cell proliferation relative to DMSO control, measured by Ki-67. Values represent mean  $\pm$  sem. A minimum of 10,000 hNPCs was counted per condition/per experiment. Data were analysed by one-way ANOVA with Tukey's multiple comparison test, \*  $p < 0.05$ , \*\*  $p < 0.001$ , \*\*\*  $p < 0.0001$ . Values represent mean  $\pm$  sem. The number inside the bar represents the number of experiments in each group.

## Discussion

The use of *in vitro* models can potentially clarify mechanisms related to proliferation and differentiation of new-born neurons (Cai & Grabel 2007), which happens massively during embryogenesis but also later in specific brain regions. Numerous studies have shown a close relationship between disturbed adult neurogenesis and depression, highlighting the need for more efficacious and faster-acting treatments. Thus, the aim of this study was to investigate the effects of harmine, a compound with potential antidepressant properties, on human neural progenitor cells derived from pluripotent stem cells. Here we show that

259 harmine increases proliferation of hNPCs positive for both nestin and GFAP *in*  
 260 *vitro*, having inhibition of DYRK1 as the possible mechanism.

261 We describe, in cell cultures containing more than 90% of hNPCs, that treatment  
 262 with harmine increased proliferation without DNA damage or cell death. These  
 263 results are consistent with findings published by Hämmerle and others (2011), in  
 264 which exposure of chick embryos to harmine resulted in a strong increase in  
 265 BrdU incorporation and number of mitotic cells in the spinal cord.

266 Interestingly, harmine treatment also increased the number of early progenitor  
 267 cells, stained with both GFAP and Nestin. At first, this result suggests that  
 268 harmine drives the differentiation of hNPCs into radial glial cells, which are the  
 269 major source of neuronal and glial progenitors in the developing brain (Gotz &  
 270 Barde 2005). Similarly, in the adult hippocampus of rodents, these neural  
 271 precursors are responsible for late neurogenesis and gliogenesis (Zhao et al.  
 272 2008). In this context, levels of GFAP tend to increase on cells that shifted to a  
 273 glial fate. On the other hand, despite being GFAP+ cells, at this developmental  
 274 stage, these progenitors can also shift to a phenotype PSA-NCAM+, which can  
 275 give rise to neurons (Fukuda et al. 2003). In the light of this evidence, we suggest  
 276 that harmine could potentiate proliferation of radial glia-like cells  
 277 (GFAP+/Nestin+) derived from hNPCs, which are capable to generate both  
 278 neurons and astrocytes. Further experiments should be done in order to confirm  
 279 the terminal fate of harmine-treated hNPCs.

280 Harmine has been described as an inhibitor of MAO and DYRK1A (Gockler et al.  
 281 2009; Santillo et al. 2014). MAO inhibition increases serotonergic  
 282 neurotransmission in the adult brain (Finberg, 2014), which is a key component  
 283 of the classical antidepressant action. The main outcome of treatment with MAO  
 284 inhibitors is upregulation of cell proliferation and neurogenesis in the  
 285 hippocampus (Manev et al. 2001). On the other hand, it has been reported that  
 286 mice lacking MAO presented reduced proliferation of neural progenitor cells  
 287 (Cheng et al. 2010). In order to verify if MAO inhibition plays a role in harmine-  
 288 induced proliferation, we used the specific MAO inhibitor, pargyline. Pargyline did  
 289 not alter the levels of harmine-induced proliferation. While these results indicate

that MAO is not involved in the proliferative effects of harmine, we can not rule out that the lack of effect of pargyline is due to the absence of MAO in neural progenitor cells. In fact, MAO-dependent changes in NPCs proliferation were described late in embryonic development, mediated by serotonin (Cheng et al. 2010).

On the other hand, treatment with INDY, an inhibitor of DYRK1, induced proliferation similarly to that observed with harmine. These results are consistent with the findings of Wang and collaborators, where harmine-dependent DYRK1A inhibition increases the proliferation of pancreatic beta cells (Zhou et al. 2015). Since both harmine and INDY have multiple targets on DYRK family, including regulators of cell cycle (Becker & Sippl 2011), we should consider other potential players of INDY- and harmine-mediated increase in proliferation.

INDY can also inhibit DYRK1A closely related kinases, DYRK1B and DYRK2. In cancer studies DYRK1B and DYRK2 have been described as modulators of proliferation (Adayev et al. 2011; Zhou et al. 2015). In fact, harmine also inhibits DYRK1B and DYRK2, but the efficiency of this inhibition is, respectively, 5- and 50-fold lower in comparison to DYRK1A (Adayev et al. 2011; Bain et al. 2007; Gockler et al. 2009). Thus, DYRK1A emerges as the major candidate for mediating the increase in proliferation seen in this study. Also, it was shown that DYRK1A directly phosphorylates p53 and leads to the induction of p53 target genes, attenuating proliferation of rat and human neural progenitor cells (Park et al. 2010). Further studies are needed to reveal other aspects of human cell proliferation stimulated by harmine.

It is worth to mention that DYRK1A can also modulate migration (Pons-Espinal et al. 2013) and differentiation (Kurabayashi & Sanada 2013; Yabut et al. 2010) of neural progenitors. Neurogenesis contemplates the interplay of proliferation, migration and differentiation. While our data show that harmine stimulates proliferation of hNPCs, further studies upon migration and differentiation may clarify whether neurogenesis (or gliogenesis) are indeed increased by harmine in hNPCs.

Taken together our results suggest that harmine exert proliferative effects in

human neural progenitors, particularly in radial glia-like cells (GFAP+/Nestin+), by inhibiting DYRK1A. These findings shed light on the possible mechanisms behind the antidepressant effects of Ayahuasca described in patients.

## Abbreviations

hNPCs - human neural progenitors; DYRK - dual-specificity tyrosine phosphorylation-regulated kinase; MAO - monoamine oxidase; GFAP - Glial fibrillary acidic protein; MAP2 - Microtubule-Associated Protein 2;

## Acknowledgements

This work is part of the PhD thesis of VD. We thank Ismael Gomes, Marcelo Costa and Igor Lima da Silva for technical assistance and Dr. Mauro de Freitas Rebelo for assistance with statistical analysis.

## References

- Adayev T, Wegiel J, and Hwang YW. 2011. Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A). *Arch Biochem Biophys* 507:212-218. 10.1016/j.abb.2010.12.024
- Baharvand H, Mehrjardi NZ, Hatami M, Kiani S, Rao M, and Haghighi MM. 2007. Neural differentiation from human embryonic stem cells in a defined adherent culture condition. *Int J Dev Biol* 51:371-378. 10.1387/ijdb.72280hb
- Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, and Cohen P. 2007. The selectivity of protein kinase inhibitors: a further update. *Biochem J* 408:297-315. 10.1042/BJ20070797
- Becker W, and Sippl W. 2011. Activation, regulation, and inhibition of DYRK1A. *FEBS J* 278:246-256. 10.1111/j.1742-4658.2010.07956.x
- Cai C, and Grabel L. 2007. Directing the differentiation of embryonic stem cells to neural stem cells. *Dev Dyn* 236:3255-3266. 10.1002/dvdy.21306
- Callaway JC, Raymon LP, Hearn WL, McKenna DJ, Grob CS, Brito GS, and Mash DC. 1996. Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca. *J Anal Toxicol* 20:492-497.
- Chen SJ, Kao CL, Chang YL, Yen CJ, Shui JW, Chien CS, Chen IL, Tsai TH, Ku HH, and Chiou SH. 2007. Antidepressant administration modulates neural stem cell survival and serotonergic differentiation through bcl-2. *Curr Neurovasc Res* 4:19-29.
- Cheng A, Scott AL, Ladenheim B, Chen K, Ouyang X, Lathia JD, Mughal M, Cadet JL, Mattson MP, and Shih JC. 2010. Monoamine oxidases regulate telencephalic neural progenitors in late embryonic and early postnatal

development. *J Neurosci* 30:10752-10762. 10.1523/JNEUROSCI.2037-10.2010

DeCarolus NA, Kirby ED, Wyss-Coray T, and Palmer TD. 2015. The Role of the Microenvironmental Niche in Declining Stem-Cell Functions Associated with Biological Aging. *Cold Spring Harb Perspect Med* 5. 10.1101/cshperspect.a025874

Egeland M, Zunszain PA, and Pariante CM. 2015. Molecular mechanisms in the regulation of adult neurogenesis during stress. *Nat Rev Neurosci* 16:189-200. 10.1038/nrn3855

Farzin D, and Mansouri N. 2006. Antidepressant-like effect of harmaline and other beta-carbolines in the mouse forced swim test. *Eur Neuropsychopharmacol* 16:324-328. 10.1016/j.euroneuro.2005.08.005

Finberg JP. 2014. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release. *Pharmacol Ther.* 143(2):133-52. 10.1016/j.pharmthera.2014.02.010.

Fortunato JJ, Reus GZ, Kirsch TR, Stringari RB, Stertz L, Kapczinski F, Pinto JP, Hallak JE, Zuardi AW, Crippa JA, and Quevedo J. 2009. Acute harmaline administration induces antidepressant-like effects and increases BDNF levels in the rat hippocampus. *Prog Neuropsychopharmacol Biol Psychiatry* 33:1425-1430. 10.1016/j.pnpbp.2009.07.021

Fraga AM, Sukoyan M, Rajan P, Braga DP, Iaconelli A, Jr., Franco JG, Jr., Borges E, Jr., and Pereira LV. 2011. Establishment of a Brazilian line of human embryonic stem cells in defined medium: implications for cell therapy in an ethnically diverse population. *Cell Transplant* 20:431-440. 10.3727/096368910X522261

Fukuda S, Kato F, Tozuka Y, Yamaguchi M, Miyamoto Y, and Hisatsune T. 2003. Two distinct subpopulations of nestin-positive cells in adult mouse dentate gyrus. *J Neurosci* 23:9357-9366.

Gockler N, Jofre G, Papadopoulos C, Soppa U, Tejedor FJ, and Becker W. 2009. Harmaline specifically inhibits protein kinase DYRK1A and interferes with neurite formation. *FEBS J* 276:6324-6337. 10.1111/j.1742-4658.2009.07346.x

Gotz M, and Barde YA. 2005. Radial glial cells defined and major intermediates between embryonic stem cells and CNS neurons. *Neuron* 46:369-372. 10.1016/j.neuron.2005.04.012

Hammerle B, Ulin E, Guimera J, Becker W, Guillemot F, and Tejedor FJ. 2011. Transient expression of Mnb/Dyrk1a couples cell cycle exit and differentiation of neuronal precursors by inducing p27KIP1 expression and suppressing NOTCH signaling. *Development* 138:2543-2554. 10.1242/dev.066167

Kurabayashi N, and Sanada K. 2013. Increased dosage of DYRK1A and DSCR1 delays neuronal differentiation in neocortical progenitor cells. *Genes Dev* 27:2708-2721. 10.1101/gad.226381.113

- Labate BC, and Feeney K. 2012. Ayahuasca and the process of regulation in Brazil and internationally: implications and challenges. *Int J Drug Policy* 23:154-161. 10.1016/j.drugpo.2011.06.006
- Mahar I, Bambico FR, Mechawar N, and Nobrega JN. 2014. Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects. *Neurosci Biobehav Rev* 38:173-192. 10.1016/j.neubiorev.2013.11.009
- Malberg JE, Eisch AJ, Nestler EJ, and Duman RS. 2000. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. *J Neurosci* 20:9104-9110.
- Manev H, Uz T, Smalheiser NR, and Manev R. 2001. Antidepressants alter cell proliferation in the adult brain in vivo and in neural cultures in vitro. *Eur J Pharmacol* 411:67-70.
- Martinez de Lagran M, Benavides-Piccione R, Ballesteros-Yanez I, Calvo M, Morales M, Fillat C, Defelipe J, Ramakers GJ, and Dierssen M. 2012. Dyrk1A influences neuronal morphogenesis through regulation of cytoskeletal dynamics in mammalian cortical neurons. *Cereb Cortex* 22:2867-2877. 10.1093/cercor/bhr362
- Mazur-Kolecka B, Golabek A, Kida E, Rabe A, Hwang YW, Adayev T, Wegiel J, Flory M, Kaczmarek W, Marchi E, and Frackowiak J. 2012. Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice. *J Neurosci Res* 90:999-1010. 10.1002/jnr.23007
- Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, and Monteggia LM. 2002. Neurobiology of depression. *Neuron* 34:13-25.
- Osorio Fde L, Sanches RF, Macedo LR, Santos RG, Maia-de-Oliveira JP, Wichert-Ana L, Araujo DB, Riba J, Crippa JA, and Hallak JE. 2015. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. *Rev Bras Psiquiatr* 37:13-20. 10.1590/1516-4446-2014-1496
- Park J, Oh Y, Yoo L, Jung MS, Song WJ, Lee SH, Seo H, and Chung KC. 2010. Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells. *J Biol Chem* 285:31895-31906. 10.1074/jbc.M110.147520
- Paulsen B da S, de Moraes Maciel R, Galina A, Souza da Silveira M, dos Santos Souza C, Drummond H, Nascimento Pozzatto E, Silva H, Jr., Chicaybam L, Massuda R, Setti-Perdigao P, Bonamino M, Belmonte-de-Abreu PS, Castro NG, Brentani H, and Rehen SK. 2012. Altered oxygen metabolism associated to neurogenesis of induced pluripotent stem cells derived from a schizophrenic patient. *Cell Transplant* 21:1547-1559. 10.3727/096368911X600957
- Pons-Espinal M, Martinez de Lagran M, and Dierssen M. 2013. Environmental enrichment rescues DYRK1A activity and hippocampal adult neurogenesis in TgDyrk1A. *Neurobiol Dis* 60:18-31. 10.1016/j.nbd.2013.08.008
- Sachs BD, and Caron MG. 2015. Chronic fluoxetine increases extra-hippocampal neurogenesis in adult mice. *Int J Neuropsychopharmacol* 18. 10.1093/ijnp/pyu029



- Santillo MF, Liu Y, Ferguson M, Vohra SN, and Wiesenfeld PL. 2014. Inhibition of monoamine oxidase (MAO) by beta-carbolines and their interactions in live neuronal (PC12) and liver (HuH-7 and MH1C1) cells. *Toxicol In Vitro* 28:403-410. 10.1016/j.tiv.2013.12.006
- Sousa-Ferreira L, Aveleira C, Botelho M, Alvaro AR, Pereira de Almeida L, and Cavadas C. 2014. Fluoxetine induces proliferation and inhibits differentiation of hypothalamic neuroprogenitor cells in vitro. *PLoS One* 9:e88917. 10.1371/journal.pone.0088917
- Wang P, Alvarez-Perez JC, Felsenfeld DP, Liu H, Sivendran S, Bender A, Kumar A, Sanchez R, Scott DK, Garcia-Ocana A, and Stewart AF. 2015. A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. *Nat Med* 21:383-388. 10.1038/nm.3820
- Winner B, and Winkler J. 2015. Adult neurogenesis in neurodegenerative diseases. *Cold Spring Harb Perspect Biol* 7:a021287. 10.1101/cshperspect.a021287
- Yabut O, Domogauer J, and D'Arcangelo G. 2010. Dyrk1A overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells. *J Neurosci* 30:4004-4014. 10.1523/JNEUROSCI.4711-09.2010
- Yritia M, Riba J, Ortuno J, Ramirez A, Castillo A, Alfaro Y, de la Torre R, and Barbanoj MJ. 2002. Determination of N,N-dimethyltryptamine and beta-carboline alkaloids in human plasma following oral administration of Ayahuasca. *J Chromatogr B Analyt Technol Biomed Life Sci* 779:271-281.
- Zhao C, Deng W, and Gage FH. 2008. Mechanisms and functional implications of adult neurogenesis. *Cell* 132:645-660. 10.1016/j.cell.2008.01.033
- Zhou N, Yuan S, Wang R, Zhang W, and Chen JJ. 2015. Role of dual specificity tyrosine-phosphorylation-regulated kinase 1B (Dyrk1B) in S-phase entry of HPV E7 expressing cells from quiescence. *Oncotarget* 6:30745-30761. 10.18632/oncotarget.5222